## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 12.4% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. MRS_5 (12.5%) even more extended - blow-off risk elevated.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($56.97)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. BioMarin, Amicus Agree To $4.8bn Buyout, Combining Rare Disease Portfolios**
- Source: Citeline News & Insights | 20251219T215819 | Bullish | Relevance: 100%
- BioMarin Pharmaceutical Inc. has agreed to a $4.8 billion buyout of Amicus Therapeutics, Inc., aiming to combine their rare disease portfolios. This acquisition is reported by Joseph Haas and was announced on December 19, 2025. The deal seeks to strengthen their position in the specialized biotechnology market.

**2. Kirkland Advises Amicus Therapeutics on $4.8 Billion Sale to BioMarin**
- Source: Kirkland & Ellis LLP | 20251219T160920 | Bullish | Relevance: 100%
- Kirkland & Ellis advised Amicus Therapeutics on its definitive agreement to be acquired by BioMarin Pharmaceutical Inc. for $4.8 billion in an all-cash transaction. This acquisition will expand BioMarin's portfolio with treatments for Fabry and Pompe diseases, as well as a potential treatment for focal segmental glomerulosclerosis. The transaction is anticipated to close in the second quarter of 2026, pending regulatory and stockholder approvals.

**3. BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook**
- Source: BioMarin Pharmaceutical | 20251219T130919 | Bullish | Relevance: 100%
- BioMarin Pharmaceutical Inc. announced its definitive agreement to acquire Amicus Therapeutics for $4.8 billion in an all-cash transaction, paying $14.50 per share. This acquisition aims to expand BioMarin's rare disease product portfolio by adding Amicus's Galafold and Pombiliti + Opfolda, which are treatments for Fabry and Pompe diseases, respectively. The deal is expected to accelerate BioMarin's revenue growth, be accretive to non-GAAP diluted EPS within 12 months, and create substantial shareholder value.

**4. BioMarin Pharmaceutical Inc. agreed to acquire Amicus Therapeutics, Inc. for $4.7 billion.**
- Source: marketscreener.com | 20251219T104400 | Bullish | Relevance: 97%
- BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics, Inc. for $4.7 billion in a deal expected to close in Q2 2026. BioMarin will pay $14.5 per share in cash, financing the acquisition through cash on hand and $3.7 billion in non-convertible debt. Both companies' boards have unanimously approved the transaction.

**5. BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase**
- Source: BioSpace | 20251219T150920 | Bullish | Relevance: 96%
- BioMarin Pharmaceutical is acquiring Amicus Therapeutics in an all-cash deal worth $4.8 billion, aiming to boost its rare disease portfolio. This acquisition includes two FDA-approved drugs for Fabry disease and Pompe disease, which generated close to $600 million in sales over the last year. The move comes after BioMarin adjusted its revenue targets and divested assets that underperformed, as it seeks to accelerate revenue growth.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | Leerink Partner | down | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +15.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 11.6x attractive for 47% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.7B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 11.6 |
| Current P/E | 17.1 |
| YoY Growth | 47.1% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -3.4% to 12.4% (+15.8% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (12.4% > 10.0%), caution on chasing. MRS_5 at 12.5% confirms short-term momentum alignment. AM_20 at 12.8% shows strong absolute momentum above own 20MA. Outperforming sector by 12.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. Elevated volume (2.3x 20MA), institutional activity likely. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 12.43% (CS: 98) | Strong |
| RSI_14 | 73.4 | Overbought |
| MACD Histogram | 0.33 | Bullish |
| vs SMA20 | 1.128x | Above |
| vs SMA50 | 1.141x | Above |
| vs SMA200 | 1.055x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $61.15
- **Stop Loss:** $56.97 (6.8% risk)
- **Target:** $65.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 287
- **Position Value:** $17,550.05
- **Portfolio %:** 17.55%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.31 | $0.12 | -61.1% |
| 2025Q2 | $1.01 | $1.44 | +42.3% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*